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convincing cancer-related outcomes. Patients with PSA
≥20 ng/ml should be considered for an aggressive
approach, starting with radical surgery. Most patients need
adjuvant HT or RT. This study confirms that RP should be
considered as the first step in a multimodality approach for
clinically locally advanced PCa.
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Aim: To report the outcomes of a single institutional study
on 98 pts with clinically locally advanced prostate cancer
(PCa) and prostate-specific antigen (PSA) ≥20 ng/ml who
underwent radical prostatectomy (RP) and pelvic
lymphadenectomy (PNLD).
Patients and Methods: We performed a retrospective
review of PCa patients who had initial PSA values above
20 ng/ml (Group A), treated with RP between 1999 and
2005. Overall (OS), cancer specific (CSS), clinical
progression free (CPFS), and biochemical recurrence free
survival (BRFS) of these patients were compared with
those of other patients who had initial PSA values above
50 ng/ml (Group B). Biochemical recurrence was defined
as a double rise in PSA levels over 0.2 ng/ml after RP.
Adjuvant or salvage radiotherapy (RT) or hormonal
therapy (HT) were indicated according to institutional
protocols. OS, CSS, CPFS and BRFS were calculated for
the entire cohort and select subGroups using the Kaplan-
Meier method with log-rank test and Cox multivariate
analysis.
Results: The mean age was 66 (range IQR 61.8-71)
years, with no significant differences between Group A and
B. Mean PSA was 30.4 (range IQR 24.4-45) ng/ml. No
differences between the two groups were observed for
pathological stage, positive surgical margins and lymph
node involvement. Mean pathological Gleason score was
significantly higher for Group B (p=0.005). Mean follow-
up was 65.3 (range IQR 46.0–96.5) months. Table I
describes OS, CSS and BRFS at 5 and 10 years for Group
A and B. Only BRFS was significantly higher for Group a
vs. Group B.
Table I. 
Group A Group B p-Value
5-Year 10-Year 5-Year 10-Year 
survival survival survival survival
OS 86% 71% 83% 63% 0.65
CSS 92% 92% 89% 79% 0.67
BRFS 63% 58% 20% 20% 0.012
OS, overal survival; CSS, cancer specific survival; BRFS, biochemical
recurrence-free survival.
Conclusion: RP provided good results in cT3-4 disease.
PSA value at diagnosis in our series could not discriminate
OSS and CSS, while BRFS was lower for patients with a
PSA above 50 ng/ml. This study confirms that RP should
be considered as the first step in a multimodality approach
for locally advanced PC independently on PSA value at
diagnosis.
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